NOV 17, 202652 MINS READ
Creatine phosphate (N-phosphorylcreatine, phosphocreatine) exists predominantly as the disodium salt tetrahydrate (C₄H₈N₃O₅PNa₂·4H₂O, molecular weight 327.15 for the anhydrous form) in pharmaceutical preparations 1. The compound features a phosphoramidate bond linking the phosphate group to the guanidino nitrogen of creatine, rendering it susceptible to hydrolysis under acidic conditions or elevated temperatures. In aqueous alkaline media (pH 9–12), creatine phosphate undergoes reversible cyclization to form creatine anhydride phosphate (creatinine phosphate), a key intermediate exploited in several purification strategies 12. The zwitterionic nature of creatine phosphate at physiological pH (isoelectric point ~6.5) governs its chromatographic behavior and crystallization properties.
Key physicochemical parameters influencing purity assessment include:
The presence of structural analogs such as cyclocreatine phosphate and homocyclocreatine phosphate has been documented in synthetic preparations, requiring chromatographic resolution for pharmaceutical compliance 1213.
A breakthrough purification strategy leverages the reversible cyclization of creatine phosphate to creatinine phosphate under strongly alkaline conditions 12. The process comprises three sequential steps:
Cyclization phase: Crude creatine phosphate sodium (HPLC purity 85–92%) is dissolved in 4–6 M NaOH at 0–5°C, promoting quantitative conversion to creatinine phosphate sodium within 30–60 minutes 1. This step effectively separates lipophilic impurities (unreacted creatine phosphoryl chloride derivatives) into the organic phase during subsequent ethyl acetate extraction.
Crystallization of cyclic intermediate: Addition of ethanol (3–4 volumes) to the alkaline aqueous phase induces crystallization of creatinine phosphate sodium with >95% recovery 1. Filtration at 0–10°C removes water-soluble salts (NaCl, sodium carboxylates) and residual nucleotides.
Hydrolytic ring-opening: The purified creatinine phosphate sodium is redissolved in water and treated with dilute NaOH (pH 11–12) at 40–60°C for 2–4 hours, regenerating creatine phosphate sodium 12. Neutralization with organic acids (acetic, isooctanoic) to pH 7.0–7.5, followed by ethanol precipitation, yields creatine phosphate sodium with HPLC purity ≥99.8% and creatine/creatinine content <0.1% 1.
This method achieves molar yields of 43.7% (based on starting creatinine) and eliminates the need for toxic barium salts or heavy metal catalysts, ensuring compliance with ICH Q3D elemental impurity guidelines 1.
For creatine phosphate produced via enzymatic phosphorylation (creatine kinase-catalyzed transfer from ATP or phosphoenolpyruvate), ion-exchange purification provides superior resolution of charged impurities 39. A representative protocol involves:
Cation exchange pre-treatment: Crude reaction mixture (pH adjusted to 9.5–11.0) is passed through strong acid cation resin (e.g., Amberlite IR-120, H⁺ form) to remove Mg²⁺, Mn²⁺, and residual enzyme 3. This step reduces metal ion content to <5 ppm.
Weak anion exchange: The effluent is loaded onto a weak base resin (e.g., Amberlite IRA-67, free base form) at 4–8°C, where creatine phosphate binds while neutral creatine and creatinine pass through 3. Elution with 0.2–0.5 M NaCl gradient separates creatine phosphate from monobasic phosphate salts.
Strong anion exchange polishing: Final purification on a strong base resin (e.g., Dowex 1×8, Cl⁻ form) with 0.5–0.8 M NaCl elution removes trace ADP/AMP (retention time difference ~3 min under isocratic conditions) 34. Nanofiltration (MWCO 200–500 Da) concentrates the eluate 5–10 fold prior to ethanol precipitation.
This cascade achieves >90% recovery with final purity ≥98.5% (HPLC area normalization) and phosphate impurity content <0.02% (evaporative light scattering detection) 34. The method is scalable to 100 L batches with consistent performance across enzymatic feedstocks containing 30–150 mM creatine phosphate 3.
Medium-pressure preparative chromatography on C18 stationary phases enables production of reference standards with purity >99.9% 7. Optimized conditions include:
Lyophilization of the desalted eluate yields creatine phosphate trisodium with water content 8–12% (Karl Fischer) and organic purity 99.95% (HPLC with diode array detection, 200–400 nm scan) 7. This material serves as a primary standard for calibrating routine analytical methods.
HPLC remains the gold standard for creatine phosphate purity determination, with method validation parameters meeting USP <621> requirements 234. A widely adopted protocol employs:
Typical retention times: creatine (3.2 min), creatinine (4.8 min), creatine phosphate (6.5 min), AMP (9.1 min), ADP (11.3 min), ATP (14.7 min) under isocratic conditions at 35°C 27. Area normalization calculates creatine phosphate content, with correction for water (Karl Fischer) and inorganic ash (sulfated ash, <0.5%) 37:
Creatine Phosphate Purity (%) = (100% – Water Content – Ash Content) × HPLC Area%
Method precision: RSD <0.5% for six replicate injections; accuracy: 98.5–101.5% recovery in spiked samples 3.
Phosphate salts (KH₂PO₄, Na₂HPO₄) and other inorganic impurities lacking UV chromophores require evaporative light scattering detection (ELSD) 4. The method involves:
Samples meeting pharmaceutical specifications show no detectable phosphate peaks (retention time ~5.2 min) when analyzed at 2 mg/mL concentration 4.
Complementary techniques validate HPLC results and detect structural anomalies:
Pharmaceutical-grade creatine phosphate sodium must comply with monographs in major pharmacopeias, which specify:
Batch release testing includes stability-indicating assays (forced degradation at pH 2, pH 12, 60°C, UV light) demonstrating ≥95% recovery after 7 days 2.
Implementation of in-line Raman spectroscopy during crystallization enables real-time purity tracking 1. Multivariate calibration models (partial least squares regression) correlate spectral features (C=N stretch at 1650 cm⁻¹, phosphate symmetric stretch at 980 cm⁻¹) with offline HPLC data, achieving prediction errors <1.5% across 92–99% purity range 1. This approach reduces batch analysis time from 8 hours to <30 minutes, facilitating adaptive process control.
A commercial-scale validation (3×100 L batches) of the ion-exchange protocol 3 demonstrated:
This dataset supported regulatory approval for a sterile powder injectable (1 g/vial) in multiple jurisdictions.
Creatine phosphate sodium injections (0.5–2.0 g/dose) are clinically employed in acute myocardial infarction and cardiac surgery to preserve ATP levels during ischemia 1011. Purity requirements are stringent due to:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| ZHONGSHAN BELLING BIOTECHNOLOGY CO. LTD. | Pharmaceutical injectable formulations for myocardial protection in acute myocardial infarction and cardiac surgery requiring ultra-high purity (≥98.0%) and absence of heavy metal contamination. | High-Purity Creatine Phosphate Sodium Injectable | Achieved HPLC purity of 99.8% and content of 99.5% with 43.7% molar yield through alkaline cyclization-hydrolysis route, eliminating heavy metal residues and toxic barium salts for enhanced clinical safety. |
| CHONGQING SHENGHUAXI PHARMACEUTICAL CO. LTD. | Sterile powder injectable formulations (1g/vial) for intravenous administration in cardiovascular therapy requiring stringent endotoxin control (<0.5 EU/mg) and high chemical purity. | Creatine Phosphate Sodium Sterile Powder | Purification via alkaline cyclization to creatinine phosphate sodium followed by hydrolytic ring-opening achieves effective removal of organic impurities (creatine, creatinine <0.3%) and inorganic contaminants, meeting pharmacopeial standards for sterile powder injectables. |
| 安徽古特生物科技有限公司 | High-precision biochemical research and pharmaceutical-grade production requiring removal of enzymatic reaction byproducts, nucleotides, and metal catalysts from creatine kinase-catalyzed phosphorylation processes. | Enzymatic Synthesis Creatine Phosphate Sodium | Multi-stage ion-exchange chromatography purification achieves >90% recovery with final purity ≥98.5%, effectively removing nucleotide impurities (ATP/ADP/AMP <0.01%) and metal ions (<5 ppm) from enzymatic synthesis products. |
| XINAN PHARMACEUTICAL CO. LTD. | Injectable pharmaceutical preparations requiring ultra-high purity standards with complete removal of adenine nucleotides for cardiovascular and neuromuscular disorder treatments. | Pharmaceutical-Grade Creatine Phosphate Sodium | Ion-exchange purification with ethanol pre-treatment achieves 99.80% purity with 40% recovery rate, eliminating ATP-series substances and ensuring compliance with USP <621> requirements without introducing sulfate or barium contamination. |
| XENOPORT INC. | Treatment of ischemia, heart failure, and neurodegenerative disorders requiring enhanced tissue penetration and cellular energy metabolism support in conditions with compromised ATP production. | Membrane Permeable Creatine Phosphate Prodrugs | Development of membrane permeable prodrug formulations including cyclocreatine phosphate and homocyclocreatine phosphate analogs enabling enhanced cellular uptake and energy homeostasis in tissues with improved bioavailability. |